Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with these agents, making it difficult for branded products like Merck & Co.’s Zerbaxa, Allergan’s Avycaz, and Melinta’s Vabomere to gain uptake in earlier lines of therapy. However, rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant GNIs, and, as our primary market research shows, activity against key drug-resistant pathogens is an important driver of brand use. Furthermore, hospital-based infectious disease (ID) specialists report shifts in their approach to treating GNIs in response to the climbing rates of drug resistance.
Provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics to more effectively increase or defend your market position.
Markets covered: United States
Primary research: Survey of 104 hospital-based ID specialists in the United States
Key drugs: Avycaz, Zerbaxa, Vabomere, Invanz, Teflaro, Tygacil, Minocin, and other key GNI generic drugs